指南与共识肺结节与肺癌

指南一致性临床分期与适宜治疗对可治愈非小细胞肺癌生存的相对影响

The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer.
指南 / 共识 · Chest · 2022-02-03

同时接受两者者生存最佳(aHR 0.41,95% CI 0.26–0.63)。

要点

  • 接受指南一致性分期者更可能接受指南一致性治疗(83% vs 66%,P < .0001)。
  • 同时接受指南一致性分期与治疗者生存最佳(aHR 0.41,95% CI 0.26–0.63)。

核心结论

  • 在该多学科诊疗队列中,指南一致性分期水平较高且逐年上升,并与指南一致性治疗选择相关。
  • 指南一致性分期与指南一致性治疗对改善生存具有互补关联,支持二者与肺癌结局之间的联系。

研究设计与样本

  • 研究纳入 2014 年至 2019 年在田纳西州孟菲斯 Baptist Cancer Center 多学科胸科肿瘤项目诊断的非转移性非小细胞肺癌患者。
  • 共评估 882 例患者,按指南一致性分期 alone、指南一致性治疗 alone、两者兼具或两者均无分组。
  • 采用 Kaplan-Meier 曲线和 Cox 比例风险模型评估总生存。

主要发现

  • 882 例患者中 456 例(52%)接受了任何有创纵隔淋巴结分期。
  • 接受指南一致性分期者更可能接受指南一致性治疗(83% vs 66%;P < .0001)。
  • 与两者均未接受者相比,同时接受两者者生存最佳(aHR 0.41;95% CI 0.26–0.63),其次为仅接受指南一致性治疗者(aHR 0.60;95% CI 0.36–0.99),仅接受指南一致性分期者 aHR 0.64(95% CI 0.37–1.09)(P < .0001,log-rank 检验)。

临床怎么用

  • 在非转移性非小细胞肺癌管理中,应推行指南一致性有创纵隔淋巴结分期以促进适宜治疗选择。
  • 同时落实指南一致性分期与指南一致性治疗可能对生存改善有互补作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer management guidelines strive to improve outcomes. Theoretically, thorough staging promotes optimal treatment selection. We examined the association between guideline-concordant invasive mediastinal nodal staging, guideline-concordant treatment, and non-small cell lung cancer survival. RESEARCH QUESTION: What is the current practice of invasive mediastinal nodal staging for patients with lung cancer in a structured multidisciplinary care environment? Is guideline-concordant staging associated with guideline-concordant treatment? How do they relate to survival? STUDY DESIGN AND METHODS: We evaluated patients with nonmetastatic non-small cell lung cancer diagnosed from 2014 through 2019 in the Multidisciplinary Thoracic Oncology Program of the Baptist Cancer Center, Memphis, Tennessee. We examined patterns of mediastinal nodal staging and stage-stratified treatment, grouping patients into cohorts with guideline-concordant staging alone, guideline-concordant treatment alone, both, or neither. We evaluated overall survival with Kaplan-Meier curves and Cox proportional hazards models. RESULTS: Of 882 patients, 456 (52%) received any invasive mediastinal staging. Seventy-four percent received guideline-concordant staging; guideline-discordant staging decreased from 34% in 2014 to 18% in 2019 (P < .0001). Recipients of guideline-concordant staging were more likely to receive guideline-concordant treatment (83% vs 66%; P < .0001). Sixty-one percent received both guideline-concordant invasive mediastinal staging and guideline-concordant treatment; 13% received guideline-concordant staging alone; 17% received guideline-concordant treatment alone; and 9% received neither. Survival was greatest in patients who received both (adjusted hazard ratio [aHR], 0.41; 95% CI, 0.26-0.63), followed by those who received guideline-concordant treatment alone (aHR, 0.60; 95% CI, 0.36-0.99), and those who received guideline-concordant staging alone (aHR, 0.64; 95% CI, 0.37-1.09) compared with neither (P < .0001, log-rank test). INTERPRETATION: Levels of guideline-concordant staging were high, were rising, and were associated with guideline-concordant treatment selection in this multidisciplinary care cohort. Guideline-concordant staging and guideline-concordant treatment were complementary in their association with improved survival, supporting the connection between these two processes and lung cancer outcomes.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Meadows-Taylor MB, Faris NR, Smeltzer MP, et al. The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer. Chest. 2022. PMID: 35122751. doi:10.1016/j.chest.2022.01.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。